Key findings
- 412participants in the largest Ecuadorian study, which combined repeat-length analysis with ethnic-group comparisons and ancestry inference
- 28 of 42members of nine families carried the expansion in the 2014 family-based study, with 49–78 CAG repeats
- 21.4%of transmissions showed intergenerational instability in that family study, with marked paternal expansion
- 28 ± 2 vs 24 ± 3mean CAG repeats in Mestizo versus Kichwa participants, a statistically significant difference in a sample that cannot establish national prevalence
Abstract
Huntington's disease is an autosomal dominant neurodegenerative disorder caused by an expanded trinucleotide repeat in the first exon of the huntingtin gene. Evidence from Ecuador remains dispersed across original articles, university theses, and clinical or rehabilitation reports. This narrative review critically integrates the Ecuadorian evidence and places it within current international genetic, clinical, and therapeutic knowledge. Searches of biomedical databases, regional indexes, and institutional repositories through August 2026 identified two principal molecular cohorts, related theses, and complementary clinical publications. The largest study included 412 participants and uniquely combined repeat-length analysis with ethnic-group comparisons and ancestry inference. It demonstrated heterogeneous allele distributions among Kichwa, Mestizo, and Afro-Ecuadorian participants, but its sample was not nationally representative and cannot establish prevalence. Earlier family-based work documented pathogenic expansions, presymptomatic carriers, anticipation, and a juvenile presentation. Interpretation is limited by overlapping samples, inconsistent historical terminology, low-resolution sizing, small clinical cohorts, and the absence of national epidemiological or longitudinal data. International evidence published since the Ecuadorian studies has reframed the disease as a process driven largely by somatic expansion of the uninterrupted repeat tract in vulnerable neurons. Therapeutic development has produced contrasting signals: an intrastriatal gene therapy reportedly slowed progression relative to external controls, whereas an intrathecal antisense huntingtin-lowering program was discontinued for lack of clinical benefit. Ecuador now needs a protected registry, standardized molecular testing with genetic counseling, multidisciplinary clinical pathways, and research incorporating uninterrupted repeat length, sequence interruptions, somatic expansion, modifier genes, and prospective phenotyping aligned with international staging frameworks. The evidence can also be translated now into a tiered national care pathway that uses existing public services. Existing evidence establishes a substantive national genetic foundation while exposing inequities in access and unresolved epidemiological questions that must be addressed before Ecuadorian families can benefit from emerging disease-modifying therapies.
Introduction
Huntington's disease, historically known as Huntington’s chorea, is a progressive autosomal dominant neurodegenerative disorder characterized by a variable combination of motor, cognitive, behavioral, and psychiatric manifestations.1 The causal mutation was identified in 1993 as an unstable CAG repeat expansion in the gene then designated IT15, located at 4p16.3.2 Current consensus nomenclature designates the gene as HTT and its product as huntingtin, and recommends uniform terms for repeat-length categories.3 Each CAG repeat encodes glutamine; when the tract expands, huntingtin contains an abnormally long polyglutamine region that disrupts multiple cellular processes. However, the disease cannot be explained solely by accumulation of a toxic protein. Partial loss of normal huntingtin function, transcriptional dysregulation, impaired axonal transport, altered energy metabolism, proteostasis failure, defective autophagy, inflammation, and somatic DNA expansion also contribute to pathogenesis.4
Repeat length remains the principal genetic determinant. Alleles with 26 or fewer repeats are considered normal. Alleles with 27 to 35 repeats are classified as intermediate and generally do not cause disease in the carrier, although they may expand during transmission. Alleles with 36 to 39 repeats show reduced penetrance, whereas alleles with 40 or more repeats are associated with complete penetrance within a typical lifespan.5 Repeat length explains a substantial, but incomplete, proportion of the variation in age at onset; consequently, individuals with similar expansions may follow different clinical trajectories.6 This variability is particularly relevant in genetically diverse countries with unequal access to diagnosis, including Ecuador.
Global prevalence varies widely according to ancestry, demographic structure, founder effects, and diagnostic capacity. Prevalence is higher in populations of European ancestry and lower in many African and East Asian populations, although inadequate registries lead to underestimation.7 Latin America occupies a prominent place in the history of research on this disease because of large clusters in Venezuela, Peru, Colombia, and Brazil. A 2024 regional meta-analysis estimated a pooled prevalence of 0.64 per 100,000 inhabitants, with a very wide prediction interval, compared with 54 per 100,000 in cluster regions; juvenile forms represented approximately 8.7% of cases, and the authors considered all regional figures to be underestimates attributable to limited molecular testing and scarce specialist care.8 In Ecuador, molecular research began with family-based studies and later expanded to the population distribution of HTT alleles and genetic ancestry.
Two controversies frame this review. The first concerns the extent to which socially defined ethnic categories can be used to interpret allele distributions in an admixed population without sliding into biological determinism. The second concerns the pathogenic model itself, which has shifted from inherited polyglutamine length toward somatic expansion of the uninterrupted CAG tract, with consequences for risk interpretation and therapy. The aim of this review is to critically integrate the Ecuadorian evidence, define what can and cannot currently be concluded about the disease in Ecuador, and propose clinical, scientific, and public health priorities in light of international developments through 2026.
Methods
A structured narrative review was conducted using documents available through August 2026. PubMed/MEDLINE, Scopus, Europe PMC, LILACS/BVS, SciELO, Latindex-indexed journals, Dialnet, Crossref, Semantic Scholar, and publicly accessible Google Scholar metadata were searched, together with REDI-CEDIA, Ecuadorian journals, and the repositories of the Pontifical Catholic University of Ecuador, Universidad de Las Américas, Technical University of Ambato, National University of Chimborazo, and Central University of Ecuador. Search terms included “Huntington's disease,” “Huntington’s chorea,” “enfermedad de Huntington,” “corea de Huntington,” “HTT,” “IT15,” “CAG repeats,” “Ecuador,” and “Ecuadorian.” Eligible sources included original studies involving Ecuadorian participants, theses containing clinical or molecular data, reviews produced in Ecuador, and international publications required to interpret the national findings. For therapeutic developments not yet reported in full peer-reviewed form, primary sponsor communications were consulted and are identified as such. Samples from related documents were not combined automatically because several theses and articles arose from temporally overlapping research programs and may include the same participants.
Molecular Basis and Contemporary Interpretation of the Huntingtin Gene
The huntingtin gene encodes a protein of approximately 3,144 amino acids that is ubiquitously expressed and essential during development. Huntingtin functions as an interaction scaffold involved in vesicular transport, endocytosis, autophagy, transcriptional regulation, and neuronal survival. The exon 1 expansion promotes proteolysis and formation of N-terminal polyglutamine fragments that are particularly toxic to striatal medium spiny neurons.9 Selective neuronal vulnerability does not imply that the mutation acts only in the brain; peripheral, metabolic, muscular, and immune abnormalities have also been described.
The contemporary model has shifted part of the explanation from inherited allele size to the length of the uninterrupted CAG tract and its somatic expansion. Variants that remove the CAA and CCA interruptions may accelerate disease onset, especially in small expansions or reduced-penetrance alleles.10 Genome-wide association studies have identified modifiers in DNA maintenance and repair genes, including FAN1, MSH3, MLH1, PMS1, PMS2, and LIG1,11 and have shown that onset timing is determined by the length of the uninterrupted CAG sequence rather than by the length of the encoded polyglutamine tract.12 These genes influence the extent of repeat expansion in somatic cells over time and therefore affect when a pathogenic neuronal threshold is crossed.
Single-cell analyses of postmortem striatum have since provided direct support for this model. In striatal projection neurons, inherited alleles of 40 to 45 repeats expanded somatically to more than 100 and, in some cells, to several hundred repeats; expansion up to approximately 150 repeats had no apparent cell-autonomous effect, whereas neurons carrying longer tracts lost their transcriptional identity, activated senescence and apoptosis programs, and disappeared.13 In this view, Huntington's disease is driven by a DNA process for most of a neuron's life, and protein toxicity becomes decisive only late in a long, asynchronous somatic process. The disease therefore remains monogenic in its primary cause, but the timing of onset and progression has a complex modifier architecture, and somatic expansion itself has become a therapeutic target.
Development of Huntington's Disease Research in Ecuador
First Molecular Study of Ecuadorian Families
The earliest original article identified in this review was published by Pavón-Realpe and colleagues in 2014. Using polymerase chain reaction, nested polymerase chain reaction, and automated sequencing, the investigators genotyped 42 members of nine Ecuadorian families with a clinical diagnosis of Huntington's disease or a family history indicating risk.14 Twenty-eight individuals carried the expansion. The expanded allele contained a mean of 57 ± 7.9 CAG repeats, with a range of 49 to 78. Seven carriers had not developed chorea at the time of evaluation, illustrating the presymptomatic phase and the need to distinguish genetic status from clinically manifest disease.
The reported mean for normal alleles was 24 ± 8.4 repeats, with a range of 15 to 28; this standard deviation appears discordant with the stated range and warrants verification against source data. Two individuals carried alleles with 32 and 37 repeats, categories that require different current interpretations: 32 repeats constitute an intermediate allele, whereas 37 repeats confer reduced penetrance. An apparently de novo case with 53 repeats was also reported. This finding is important, but designation as de novo requires exclusion of nonpaternity, germline mosaicism, undetected parental intermediate alleles, and technical limitations. The study found an inverse relationship between CAG length and age at onset, intergenerational instability in 21.4% of transmissions, and marked paternal expansion, consistent with the anticipation described internationally.15
The Largest and Most Informative Study of an Ecuadorian Cohort
The largest and most comprehensive study available was published by Paz-y-Miño and colleagues in Clinical Genetics in 2017.16 Its principal strength was the integration of patients and relatives with comparisons among ethnic groups and genetic ancestry analysis. The total sample comprised 412 participants: 75 Kichwa individuals, 211 Mestizo individuals, 65 Afro-Ecuadorian individuals, 31 clinically diagnosed patients, and 30 relatives. Nested polymerase chain reaction, Sanger sequencing, and 46 ancestry-informative insertion-deletion markers were used.
In the study population, 77.20% had fewer than 28 repeats, 18.80% were classified as carrying “mutable” alleles, 2.27% had alleles described as showing incomplete penetrance, and 1.70% had more than 39 repeats. Mean repeat numbers were 24 ± 3 among Kichwa participants, 28 ± 2 among Mestizo participants, and 24 ± 3.2 among Afro-Ecuadorian participants. The difference between Mestizo and Kichwa participants was statistically significant. Ancestry analysis showed a predominantly Native American component, accompanied by European contribution and a smaller African component.
This study deserves particular emphasis for several reasons. First, it provides the largest available characterization of the HTT CAG repeat distribution in the Ecuadorian study cohort. Second, it incorporated ethnic diversity, an essential consideration in an admixed population. Third, it proposed that the higher mean observed among Mestizo participants might reflect a larger reservoir of alleles susceptible to intergenerational expansion. This hypothesis is biologically plausible because the distribution of high-normal and intermediate alleles contributes to population differences in the emergence of new expansions.17 Nevertheless, a population mean is not equivalent to individual clinical risk, and the term “mutable” should be aligned with current nomenclature.3 The comparison was based on a convenience sample and cannot establish national prevalence or attribute causality to ancestry. In addition, the published ancestry values appear to have been expressed or rounded in a manner that requires verification of the scale before they are reproduced as exact proportions.
The study's main contribution is its demonstration that the HTT allele landscape is not uniform across the groups examined. Its principal limitation is that it was not designed as a nationally representative survey. It also did not assess CAA and CCA interruptions, somatic mosaicism, or modifier variants, areas of knowledge that developed substantially after publication. Reassessment of this cohort using high-resolution capillary electrophoresis, repeat-tract sequencing, and longitudinal follow-up would have considerable international value.
Contributions from University Theses
A thesis submitted by Paredes Corrales to the Pontifical Catholic University of Ecuador in 2014 examined 57 individuals from five families treated at different public health facilities during 2012.18 Twelve individuals were reported to carry one expanded and one normal allele, including one juvenile case. The study confirms that the disease occurred in families receiving care through the public health system and that early-onset forms were present. However, visualization in 3% agarose gels and estimation using ImageJ provide lower resolution than capillary electrophoresis or sequencing, particularly near the 35- to 40-repeat diagnostic boundaries. These findings should be regarded as exploratory and should not be used in isolation for predictive decisions.
The thesis by Pavón Realpe, deposited at Universidad de Las Américas in 2015, arose from the research program that produced the 2014 family study and should not be counted as an independent cohort.19 Similarly, the 2017 thesis by Eras Muñoz examined the ancestry of Ecuadorian patients carrying an IT15 mutation using 46 ancestry-informative insertion-deletion markers and provided the analytical basis for interpreting the predominantly Native American ancestry observed in the study population.20 Both documents are valuable because they preserve methodological detail and results that are often condensed in journal articles; however, potential sample overlap precludes aggregation without participant-level reconciliation.
Reviews, Rehabilitation, and Clinical Reports
Ecuadorian scholarly output also includes narrative reviews. Vallejo Zambrano and colleagues summarized disease genetics, clinical manifestations, and treatment in 2020.21 In 2024, Mejía Gallegos and colleagues reviewed symptoms, quality of life, rehabilitation, and therapeutic alternatives.22 These publications have educational value but do not provide additional genotypes, prevalence estimates, or longitudinal follow-up of Ecuadorian patients. A thesis from the National University of Chimborazo reviewed multimodal exercise as a rehabilitation strategy,23 while academic reports and case studies have described chorea in older adults and dementia associated with the disease. These sources are clinically informative but cannot quantify the national burden.
A frequent error in literature reviews should also be avoided: publication in an Ecuadorian journal does not necessarily indicate that the patients studied were Ecuadorian. The dental case report published in Odontología, a journal of the Central University of Ecuador, was written primarily by Brazilian authors.24 It should therefore be cited as international clinical experience published in Ecuador, not as Ecuadorian epidemiological evidence.
Integrated Interpretation of the Ecuadorian Evidence
Taken together, the evidence documents Ecuadorian families with fully penetrant expansions, presymptomatic carriers, at least one juvenile case, intermediate and reduced-penetrance alleles, intergenerational anticipation, and heterogeneity in the CAG repeat distribution (Table 1). It also indicates that admixture and ancestry composition should be considered without converting socially constructed ethnic categories into rigid biological explanations. Genetic ancestry is continuous and probabilistic; it neither replaces the individual genotype nor supports racial determinism.
Table 1. Ecuadorian evidence directly related to Huntington's disease. Samples should not be pooled without verification of overlap.
| Source | Population or focus | Principal finding | Main limitation |
|---|---|---|---|
| Pavón-Realpe et al., 2014 | 42 members of 9 families | 28 expansion carriers; 49–78 CAG repeats; presymptomatic carriers and intergenerational instability | Family-based sample; not nationally representative |
| Paredes Corrales, 2014 (thesis) | 57 individuals from 5 families | 12 expansions; 1 juvenile case | Limited resolution of gel-based sizing |
| Paz-y-Miño et al., 2017 | 412 participants from several groups | CAG differences between Mestizo and Kichwa participants; predominantly Native American ancestry | Convenience sample; cannot estimate prevalence |
| Eras Muñoz, 2017 (thesis) | Patients with expanded HTT alleles | Ancestry analysis using 46 ancestry-informative insertion-deletion markers | Possible overlap with the published cohort |
There is no basis for asserting an Ecuadorian prevalence of 1 per 10,000. That figure was derived from external populations and was used only as background in national publications. It is also invalid to extrapolate cohort percentages to Ecuador's population of nearly 17 million inhabitants recorded in the 2022 census. Participants were recruited because of family history, diagnosis, or membership in selected groups rather than through epidemiological sampling. The actual number of affected individuals, presymptomatic carriers, and at-risk families remains unknown.
The reported allele distributions, the categories used in each study, and the provenance of every cohort are summarized in Figure 1. Reading the Ecuadorian series against present thresholds shows where historical terminology and current nomenclature diverge, and makes explicit which observations derive from independent samples and which do not.
Molecular Diagnosis and Genetic Counseling
Molecular diagnosis should demonstrate a heterozygous HTT expansion using a validated method that accurately determines repeat number. Capillary electrophoresis is suitable for most alleles; discordant results, large expansions, apparent homozygosity, or strong clinical suspicion require complementary methods such as triplet-primed polymerase chain reaction, Southern blotting, or long-read sequencing.25 Reports should state the repeat number of both alleles and the interpretive category using current terminology.3 Assays based solely on conventional gel electrophoresis are inadequate for resolving borderline alleles.
Diagnostic testing in a symptomatic individual differs fundamentally from predictive testing in a healthy person at risk. Predictive testing should not be offered as an isolated laboratory examination. International recommendations require informed consent, neurological and psychological assessment, pretest and post-test counseling, confidentiality, and a support plan.26 Predictive testing is generally avoided in asymptomatic minors because no preventive intervention has been shown to provide benefit during childhood and future autonomy should be protected. Testing a child with clinical features suggestive of juvenile Huntington's disease is diagnostic rather than predictive and follows different considerations.
In Ecuador, the concentration of services in Quito and Guayaquil, private costs, and the scarcity of multidisciplinary teams create inequitable access. A public care pathway should integrate neurology, clinical genetics, psychology or psychiatry, social work, rehabilitation, nutrition, and palliative care. Every positive result has implications for an entire family network: each child of a heterozygous individual has a 50% probability of inheriting the expansion, but inheritance is not certain. Information must be communicated without reproductive coercion or stigmatization.
Treatment and Comprehensive Care
No therapy has yet been shown in a randomized controlled trial to halt or reverse Huntington's disease, and no disease-modifying treatment has received regulatory approval to date. Treatment is symptomatic and should be tailored to the phenotype. Tetrabenazine, deutetrabenazine, and, since 2023, valbenazine reduce chorea through vesicular monoamine transporter 2 inhibition;27,28 antipsychotic agents may be useful when chorea coexists with irritability, psychosis, or aggression.27 Depression, anxiety, sleep disorders, weight loss, dysphagia, communication impairment, and fall risk require systematic management. Nonpharmacological care includes physiotherapy, occupational therapy, speech and swallowing therapy, nutritional support, environmental adaptation, caregiver education, and advance care planning.
Huntingtin-lowering programs have shown that engaging the causal gene does not guarantee clinical efficacy. The intrathecal antisense oligonucleotide tominersen produced dose-dependent reductions in cerebrospinal fluid mutant huntingtin in an early-phase trial,29 but the phase 3 GENERATION HD1 trial was stopped after the more frequent dosing regimen was associated with unfavorable trends in patients with manifest disease.30 The subsequent phase 2 GENERATION HD2 study, conducted in participants with earlier disease, lowered mutant huntingtin and neurofilament light chain without meaningful clinical benefit after 16 months, and the sponsor discontinued the program in July 2026.31
In contrast, a one-time intrastriatal adeno-associated virus gene therapy delivering a huntingtin-lowering microRNA (AMT-130), administered by magnetic resonance imaging-guided neurosurgery, was reported to slow progression on the composite Unified Huntington's Disease Rating Scale by 75% at 36 months in 12 high-dose recipients compared with a propensity score-matched external control derived from the Enroll-HD natural history dataset.32 These results have so far been communicated primarily through sponsor announcements rather than full peer-reviewed reports, rely on external rather than concurrent controls, and involve very small numbers. After a period of regulatory disagreement regarding external controls, the United States Food and Drug Administration indicated in June 2026 that the 3-year analysis could serve as the primary basis for an accelerated-approval application, conditional on a confirmatory study.33 Scientific caution remains essential; nonetheless, the contrast between the two programs suggests that route of delivery, regional tissue exposure, and disease stage may be as decisive as the molecular target.
For Ecuador, these developments carry an equity dimension. Access to any disease-modifying therapy will require reliable molecular confirmation, standardized phenotyping and staging, longitudinal follow-up, stereotactic neurosurgical capacity for intraparenchymal delivery, ethical governance, laboratory quality assurance, and pricing and reimbursement policies that do not reproduce the existing geographic and economic gradients. Without these conditions, therapeutic progress achieved elsewhere may widen, rather than narrow, the gap for Ecuadorian families.
Palliative care is not equivalent to therapeutic abandonment. Drawing on experience from Peru, Espinoza-Suárez and colleagues emphasized the importance of primary care, advance care planning, and caregiver support in a disease that progresses over many years.34 This approach is directly relevant to Ecuador, where daily caregiving responsibilities often fall on women within the family and economic deterioration may accompany the loss of employment of both patients and caregivers.
Knowledge Gaps
The principal gap is epidemiological. Ecuador has no national registry, province-level prevalence estimates, or published data on incidence, mortality, mean age at onset, or diagnostic delay. The numbers of families receiving counseling, predictive tests performed, patients lost to follow-up, and economic or cultural barriers are also unknown. Absence of data does not mean absence of disease; it reflects institutional invisibility.
The second gap is genomic. Ecuadorian studies appropriately focused on CAG repeat number and ancestry, but current investigation should determine uninterrupted CAG length, loss-of-interruption variants, somatic expansion, and DNA repair modifiers. International studies have shown that the exact sequence architecture of the locus can alter onset and progression in carriers of small expansions.35 Reanalysis of alleles containing 27 to 39 repeats would be particularly valuable, as would characterization of modifier variant frequencies in populations of predominantly Native American ancestry, which remain underrepresented in modifier studies.
The third gap is longitudinal and social. No Ecuadorian publications have related genotype to Unified Huntington's Disease Rating Scale measures, neuroimaging, fluid biomarkers such as neurofilament light chain, psychiatric manifestations, quality of life, caregiver burden, or survival. The Huntington's Disease Integrated Staging System, which classifies individuals from birth according to biological, clinical, and functional landmarks, now provides a common framework for research and trial eligibility.36 The Enroll-HD platform has demonstrated the value of standardized observational cohorts for understanding natural history and, as the AMT-130 program illustrates, for supplying comparator data in therapeutic development.32,37 Participation by Ecuadorian centers would allow international comparison while preserving locally relevant information.
Priorities for Research and Care in Ecuador
Ecuador requires a phased strategy. First, a voluntary, protected, and clinically useful registry should be created, using anonymized identifiers to prevent duplicate enrollment across institutions. Second, a referral network should establish uniform protocols for diagnosis, predictive testing, mental health care, and follow-up. Third, previously studied families should be recontacted, and recruitment should be extended across the Coastal, Andean, and Amazon regions without equating ethnic identification with genetic homogeneity. Fourth, repeat-tract sequencing, somatic expansion measurement, and a panel of DNA repair modifiers should be incorporated. Fifth, social outcomes should be measured, including employment loss, dependence, violence, suicide, caregiver burden, and access to disability support and palliative care. Sixth, the health system should begin preparing for eventual access to disease-modifying therapies through staging-based clinical records and regional agreements.
Consent procedures should address secondary use, recontact, international data sharing, and return of findings. Genomic data are familial: they describe the participant but may also reveal risks to relatives who did not request that information. Governance should include patient representatives, clinicians, geneticists, bioethicists, and health authorities. Research cannot be limited to DNA collection; it should return diagnostic benefit, sustained support, and local capacity.
Practical Application: From Dispersed Evidence to a Tiered National Pathway
The evidence assembled here can be converted into an operational service model without waiting for new epidemiological studies. Three findings are already firm enough to act upon. Affected families are dispersed across public facilities rather than concentrated in a single centre, which means that case identification must begin in primary care. The sizing methods used in parts of the national literature cannot reliably resolve alleles at the 35- to 40-repeat boundary, which means that confirmatory testing must be centralized. Participants may appear in more than one study or institution, which means that any national count requires anonymized reconciliation before aggregation.
Table 2 translates these three constraints into a four-level pathway that uses services Ecuador already operates. Each level is defined by the actions it can realistically perform, the minimum resource required to perform them, and a single indicator that can be reported without new infrastructure. The design deliberately separates identification from testing: primary care teams identify and refer but do not order molecular studies, which protects families from predictive results delivered without counseling.
Table 2. Proposed tiered pathway for Huntington's disease care and data collection in Ecuador, using services currently available in the public system.
| Level of care | Core actions | Minimum requirement | Indicator reported |
|---|---|---|---|
| Primary care and community teams | Identify at-risk families; record family history over three generations; refer rather than test; support caregivers | Trained family physician; standard referral form | Families identified and referred each year |
| Provincial or regional hospital | Confirm the clinical phenotype; apply a standard staging record; exclude phenocopies; begin symptomatic treatment and rehabilitation | Neurologist; validated staging instrument | Median interval from first symptom to specialist assessment |
| National reference centre | Perform diagnostic and predictive testing with pretest and post-test counseling; report both allele sizes; assign an anonymized identifier | Capillary electrophoresis with triplet-primed amplification; multidisciplinary team | Tests performed; proportion with documented counseling |
| National registry and research platform | Reconcile participants across institutions; follow outcomes; prepare staging data for trial eligibility | Anonymized identifier; governance committee including patient representatives | Duplicate-free national case count |
Two practical consequences follow. First, the pathway produces a denominator. Once referrals, confirmed diagnoses, and counseling episodes are counted with anonymized identifiers, Ecuador obtains its first duplicate-free national case series, which is the prerequisite for every prevalence estimate the present literature cannot supply. Second, the pathway is a trial-readiness instrument. Standardized staging records and documented molecular confirmation are precisely the eligibility materials that international studies require, so the same effort that improves care today also determines whether Ecuadorian families can be considered for disease-modifying therapies tomorrow. The registry is therefore the highest-yield single investment, because it converts clinical contacts that already occur into usable national data.
Conclusions
Ecuadorian research on Huntington's disease is limited but substantive. The family study by Pavón-Realpe and colleagues established the presence of pathogenic expansions, presymptomatic carriers, anticipation, and instability. The study by Paz-y-Miño and colleagues decisively expanded the field by examining 412 participants and integrating ethnic-group comparisons with ancestry analysis, making it the largest national reference. Theses from the Pontifical Catholic University of Ecuador and Universidad de Las Américas contributed additional family observations, methodological detail, and ancestry analyses, although their samples may overlap with the published studies.
The available evidence cannot establish national prevalence or support comparisons among provinces. Nor does it support the claim that any ethnic group is biologically destined to develop the disease. It does demonstrate variation in the HTT allele distribution, the presence of Ecuadorian families with substantial clinical burden, and a scientific foundation sufficient to support a new phase of research. That phase should integrate molecular genetics, somatic expansion biology, neurology, mental health, rehabilitation, social sciences, and public policy. In the meantime, the tiered pathway proposed here shows that the existing evidence is already sufficient to organize care, protect families, and build a national denominator. The priority is not merely to count CAG repeats, but to translate genetic knowledge into responsible diagnosis, family protection, and equitable care, so that the first disease-modifying therapies do not become another marker of inequality.
Declarations
- Author Contributions
- César Paz-y-Miño: Conceptualization; literature search; data curation; critical analysis; writing – original draft; writing – review and editing. Paola E. Leone: Literature search; data curation; critical analysis; writing – original draft; writing – review and editing. Both authors approved the final version of the manuscript and agree to be accountable for all aspects of the work.
- Conflict of Interest Statement
- The authors have no conflicts of interest to declare.
- Funding Statement
- The authors received no specific funding for this work.
- Ethics Statement
- Not applicable. This narrative review did not involve new research with human participants or animals and used only publicly available, cited sources. No new data were created or analyzed; all sources reviewed are cited in the article.
References
- McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018;25(1):24-34. doi:10.1111/ene.13413
- The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-983. doi:10.1016/0092-8674(93)90585-E
- DiFiglia M, Leavitt BR, Macdonald D, Thompson LM; Huntington's Disease Nomenclature Working Group. Towards standardizing nomenclature in Huntington's disease research. J Huntingtons Dis. 2024;13(2):119-131. doi:10.3233/JHD-240044
- Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005. doi:10.1038/nrdp.2015.5
- Nopoulos PC. Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci. 2016;18(1):91-98. doi:10.31887/DCNS.2016.18.1/pnopoulos
- Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65(4):267-277. doi:10.1111/j.1399-0004.2004.00241.x
- Rawlins MD, Wexler NS, Wexler AR, et al. The prevalence of Huntington's disease. Neuroepidemiology. 2016;46(2):144-153. doi:10.1159/000443738
- Medina Escobar A, Pringsheim T, Gautreau S, et al. Epidemiology of Huntington's disease in Latin America: a systematic review and meta-analysis. Mov Disord. 2024;39(11):1907-1921. doi:10.1002/mds.29929
- Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89(5):910-926. doi:10.1016/j.neuron.2016.02.003
- Wright GEB, Collins JA, Kay C, et al. Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease. Am J Hum Genet. 2019;104(6):1116-1126. doi:10.1016/j.ajhg.2019.04.007
- Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. Identification of genetic factors that modify clinical onset of Huntington's disease. Cell. 2015;162(3):516-526. doi:10.1016/j.cell.2015.07.003
- Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. CAG repeat not polyglutamine length determines timing of Huntington's disease onset. Cell. 2019;178(4):887-900.e14. doi:10.1016/j.cell.2019.06.036
- Handsaker RE, Kashin S, Reed NM, et al. Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease. Cell. 2025;188(3):623-639.e19. doi:10.1016/j.cell.2024.11.038
- Pavón-Realpe VH, Jaramillo-Koupermann G, López-Cortés A, et al. Mutation status of the IT-15 (HTT) gene in Ecuadorian families with Huntington's disease. Arch Neurocien (Mex). 2014;19(2):73-78. doi:10.31157/an.v19i2.36
- Wheeler VC, Persichetti F, McNeil SM, et al. Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet. 2007;44(11):695-701. doi:10.1136/jmg.2007.050930
- Paz-y-Miño C, Salazar-Ruales C, García-Cárdenas JM, et al. Study of the Huntington's disease IT-15 gene in different ethnic groups in Ecuador. Clin Genet. 2017;92(5):544-547. doi:10.1111/cge.13028
- Kay C, Collins JA, Miedzybrodzka Z, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016;87(3):282-288. doi:10.1212/WNL.0000000000002858
- Paredes Corrales JF. Determinación del número de tripletas CAG del gen IT15 en individuos con antecedentes familiares de enfermedad de Huntington atendidos en unidades operativas de salud pública del Ecuador, 2012. Thesis. Pontificia Universidad Católica del Ecuador; 2014.
- Pavón Realpe VH. Estado de la mutación del gen IT-15 (HTT) en familias ecuatorianas con enfermedad de Huntington. Thesis. Universidad de las Américas; 2015.
- Eras Muñoz EN. Determinación de los niveles preliminares de ancestría en pacientes de la población ecuatoriana con mutación en el gen IT-15. Thesis. Universidad de las Américas; 2017.
- Vallejo Zambrano CR, Steinzappir Navia MA, Ávila Meza SA, et al. Síndrome de Huntington: revisión bibliográfica y actualización. RECIMUNDO. 2020;4(4):392-398. doi:10.26820/recimundo/4.(4).octubre.2020.392-398
- Mejía Gallegos A, García Tobón M, Guamán Mariscal E, Murillo Brunes A. La enfermedad de Huntington, síntomas y tratamiento. J Sci Res. 2024;9(1):128-143.
- Ochoa Morejón AJ. Ejercicio multimodal en pacientes con enfermedad de Huntington. Thesis. Universidad Nacional de Chimborazo; 2023.
- Cançado Figueiredo M, Borges B, Vianna Potrich AR, Back Gouvêa D, Liberman J. Atención odontológica en un paciente con síndrome raro: enfermedad de Huntington. Reporte de caso. Odontología. 2021;23(1):e2652. doi:10.29166/odontologia.vol23.n1.2021-e2652
- Losekoot M, van Belzen MJ, Seneca S, et al. EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet. 2013;21(5):480-486. doi:10.1038/ejhg.2012.200
- MacLeod R, Tibben A, Frontali M, et al. Recommendations for the predictive genetic test in Huntington's disease. Clin Genet. 2013;83(3):221-231. doi:10.1111/j.1399-0004.2012.01900.x
- Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease. Neurology. 2012;79(6):597-603. doi:10.1212/WNL.0b013e318263c443
- Furr Stimming E, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6):494-504. doi:10.1016/S1474-4422(23)00127-8
- Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington's disease. N Engl J Med. 2019;380(24):2307-2316. doi:10.1056/NEJMoa1900907
- McColgan P, Thobhani A, Boak L, et al. Tominersen in adults with manifest Huntington's disease. N Engl J Med. 2023;389(23):2203-2214. doi:10.1056/NEJMoa2300400
- F. Hoffmann-La Roche Ltd. Update on two clinical studies: GENERATION HD2 (tominersen) and POINT-HD (RG6496). Community letter. July 9, 2026. Accessed September 18, 2026. https://en.hdbuzz.net/wp-content/uploads/2026/07/Roche-GENERATION-HD2-_-POINT-HD-global-patient-community-letter-July2026.pdf
- uniQure N.V. uniQure announces positive topline results from pivotal phase I/II study of AMT-130 in patients with Huntington's disease. News release. September 24, 2025. Accessed September 18, 2026. https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii
- uniQure N.V. uniQure announces plan for BLA submission for AMT-130 in Huntington's disease. News release. June 17, 2026. Accessed September 18, 2026. https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons
- Espinoza-Suárez NR, Palacios-García J, Morante-Osores MR. Cuidados paliativos en la enfermedad de Huntington: perspectivas desde la atención primaria de salud. Rev Neuropsiquiatr. 2016;79(4):230-238. doi:10.20453/rnp.v79i4.2977
- Heinzmann A, Petit E, Dawson J, et al. Sequence variants in small CAG repeat expansions of the HTT gene and disease onset and progression in Huntington disease. Neurology. 2026;106(1):e214404. doi:10.1212/WNL.0000000000214404
- Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington's disease: the Integrated Staging System. Lancet Neurol. 2022;21(7):632-644. doi:10.1016/S1474-4422(22)00120-X
- Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, et al. Data analytics from Enroll-HD, a global clinical research platform for Huntington's disease. Mov Disord Clin Pract. 2017;4(2):212-224. doi:10.1002/mdc3.12388
Article information
Authors
- César Paz-y-MiñoMedical Geneticist, Facultad de Ciencias de la Salud "Eugenio Espejo", Universidad UTE, Quito, EcuadorCorresponding author · [email protected]
- Paola E. LeoneBiologist and Geneticist, Laboratorio de Genética y Genómica, Sociedad de Lucha Contra el Cáncer (SOLCA), Quito, Ecuador
How to cite
Paz-y-Miño, C., Leone, P. E., 2026. Huntington's disease in Ecuador: Genetic evidence, clinical gaps, and national priorities. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0672
Record
- Journal
- Medical Research Archives
- Issue
- Vol 14 No 10 (2026)
- Section
- Review Articles
- Published
- 31 October 2026
- ISSN
- 2375-1924
- Downloads
- 75
Copyright and licence
Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.